Lighter chemo, same punch? new combo aims to spare older lung cancer patients harsh side effects

NCT ID NCT06731413

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a lower dose of chemotherapy combined with an immunotherapy drug can be a safer and still effective first treatment for older adults (70+) or those who are frail with advanced non-small cell lung cancer. The main goal is to see if fewer people have to stop chemo due to side effects. About 40 participants will receive this reduced-dose combination, and doctors will track how well the cancer responds.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • VCU Health Tappahannock Hospital

    RECRUITING

    Tappahannock, Virginia, 22560, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Virginia Commonwealth University

    RECRUITING

    Richmond, Virginia, 23298, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••